Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma

Event

Med Learning Group TeleECHO. Event URL

Overview

This case-based virtually live activity is designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma.

This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement